Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Fenofibrate treatment in patients with primary biliary cirrhosis.

Literature DB >> 12190200

Fenofibrate treatment in patients with primary biliary cirrhosis.

Hiromasa Ohira, Yukio Sato, Takato Ueno, Michio Sata.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2002 PMID： 12190200 DOI： 10.1111/j.1572-0241.2002.05944.x

Source DB: PubMed Journal: Am J Gastroenterol ISSN： 0002-9270 Impact factor: 10.864

Keyword Cloud
Cited

× No keyword cloud information.

25 in total

1. Fenofibrate-induced liver injury.

Authors: Kazufumi Dohmen; Chun Yang Wen; Shinya Nagaoka; Koji Yano; Seigo Abiru; Toshihito Ueki; Atsumasa Komori; Manabu Daikoku; Hiroshi Yatsuhashi; Hiromi Ishibashi
Journal: World J Gastroenterol Date: 2005-12-28 Impact factor: 5.742

Review 2. Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics.

Authors: Amitkumar Patel; Anil Seetharam
Journal: J Clin Exp Hepatol Date: 2016-10-21

3. Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis.

Authors: Runalia Bahar; Kimberly A Wong; Chung H Liu; Christopher L Bowlus
Journal: Gastroenterol Hepatol (N Y) Date: 2018-03

Review 4. New therapies for primary biliary cirrhosis.

Authors: Annarosa Floreani; Irene Franceschet; Lisa Perini; Nora Cazzagon; M Eric Gershwin; Christopher L Bowlus
Journal: Clin Rev Allergy Immunol Date: 2015-06 Impact factor: 8.667

5. Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis.

Authors: Zhigan Jiang; Xing Liu; Zhiliang Yuan; Haiying He; Jing Wang; Xiao Zhang; Zhen Gong; Lijuan Hou; Liang Shen; Fengxun Guo; Jiliang Zhang; Jianhua Wang; Deming Xu; Zhuowei Liu; Haijun Li; Xiaoxin Chen; Chaofeng Long; Jian Li; Shuhui Chen
Journal: ACS Med Chem Lett Date: 2019-06-24 Impact factor: 4.345

6. Statins, Fibrates, and Other Peroxisome Proliferator-Activated Receptor Agonists for the Treatment of Cholestatic Liver Diseases.

Authors: Alanna M K Dubrovsky; Christopher L Bowlus
Journal: Gastroenterol Hepatol (N Y) Date: 2020-01

Fenofibrate treatment in patients with primary biliary cirrhosis.

1. Fenofibrate-induced liver injury.

Review 2. Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics.

3. Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis.

Review 4. New therapies for primary biliary cirrhosis.

5. Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis.

6. Statins, Fibrates, and Other Peroxisome Proliferator-Activated Receptor Agonists for the Treatment of Cholestatic Liver Diseases.

Review 7. Proposed therapies in primary biliary cholangitis.

8. Fenofibrate in primary biliary cirrhosis: a pilot study.

9. Fibrates as adjuvant therapy for chronic cholestatic liver disease: its time has come.

10. Treatment of autoimmune liver disease: current and future therapeutic options.